Renalytix AI upbeat on latest 'KidneyIntelX' study results

The AIM-traded firm said the results of the study, which was the second peer-reviewed clinical validation study on KidneyIntelX, had been published in Diabetologia, the official journal of the European Association for the Study of Diabetes (EASD).

It put the strong performance of the KidneyIntelX platform down to its blood-based biomarker technologies, exclusively licensed from the Joslin Diabetes Center and the Mount Sinai Health System.

Renalytix AI said that notably, KidneyIntelX was observed to be “highly effective” at both ends of the risk spectrum.

In the study, KidneyIntelX more accurately identified and segmented patients into three risk categories, being low, intermediate and high, when compared to clinical models, including the current standard of care, the ‘KDIGO’ risk stratification algorithm.

When guideline-recommended urine albumin to creatinine ratio testing was performed, the positive predictive value for progressive decline in kidney function was 69% for those scored as high-risk by KidneyIntelX, versus the 40% identified as highest-risk by KDIGO categorisation.

That was a 72% improvement compared to standard of care.

In addition, 7% of those scored as low-risk by KidneyIntelX experienced progression, making for a negative predictive value of 93%.

“Given these additional clinical study findings, we are confident that KidneyIntelX will be adopted as part of the standard of care in assessing the risk of progressive kidney decline in individuals with early-stage diabetic kidney disease,” said the company’s chief medical officer, Michael Donovan.

“These results published in Diabetologia further validate our rigorous scientific and clinical approach, which is focused on early detection and aggressive clinical intervention for those found to be at the highest risk.”

At 1046 BST, shares in Renalytix AI were up 1.46% at 937.5p.